Characterization of urinary insulin-like growth factor binding proteins

Yukihiro Hasegawa, Pinchas Cohen, Peter Yorgin, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The insulin-like growth factors (IGFs) are important mitogens that are present in many body fluids, where they are commonly bound with high affinity to IGF binding proteins (IGFBPs). We investigated human urine for the pres-ence of IGFBPs. Western ligand blots of concentrated, dialyzed normal urine disclosed the presence of two major bands with IGF binding activity, one at 40-44 kilodaltons and another at 31 kDa. Deglycosylation with endoglycosidase F, and immunoprecipitation with αHEC1 antibody revealed these proteins to be hIGFBP-3 and hIGFBP-2, respectively. Comparison of IGFBPs in normal serum and urine showed a reversal of the hIGFBP-2/hIGFBP-3 ratio in urine compared to serum, with hIGFBP-2 being the predominant binding protein in normal urine. The 150 kDa form of hIGFBP-3 was absent in normal urine. In patients with renal disease, the urinary IGFBP (U-IGFBP) pattern was altered. Patients with glomerular disease and proteinuria had elevated U-hIGFBP-3, whereas patients with renal failure who displayed increased urinary β-2-microglobulin had a dramatic increase in U-hIGFBP-1, in the face of normal serum IGFBP profiles. In conclusion, we have documented the presence of IGFBPs in the urine of normal and diseased individuals. The presence of IGFBPs in urine may complicate the assessment of IGF measurements in urine. U-IGFBPs may be potential clinical markers in renal diseases. Additional studies are required before the origin of urinary IGFBPs in both normal and pathological conditions will be definitively established.

Original languageEnglish (US)
Pages (from-to)830-835
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume74
Issue number4
StatePublished - Apr 1992
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Urine
Somatomedins
Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase
Kidney
Body fluids
Body Fluids
Serum
Mitogens
Proteinuria
Immunoprecipitation
Renal Insufficiency
Blood Proteins
Carrier Proteins
Biomarkers
Western Blotting
Ligands
Antibodies

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Hasegawa, Y., Cohen, P., Yorgin, P., & Rosenfeld, R. R. (1992). Characterization of urinary insulin-like growth factor binding proteins. Journal of Clinical Endocrinology and Metabolism, 74(4), 830-835.

Characterization of urinary insulin-like growth factor binding proteins. / Hasegawa, Yukihiro; Cohen, Pinchas; Yorgin, Peter; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 74, No. 4, 04.1992, p. 830-835.

Research output: Contribution to journalArticle

Hasegawa, Y, Cohen, P, Yorgin, P & Rosenfeld, RR 1992, 'Characterization of urinary insulin-like growth factor binding proteins', Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 4, pp. 830-835.
Hasegawa, Yukihiro ; Cohen, Pinchas ; Yorgin, Peter ; Rosenfeld, Ronald (Ron). / Characterization of urinary insulin-like growth factor binding proteins. In: Journal of Clinical Endocrinology and Metabolism. 1992 ; Vol. 74, No. 4. pp. 830-835.
@article{3ea08c616d944a05b17a5298f5375f1d,
title = "Characterization of urinary insulin-like growth factor binding proteins",
abstract = "The insulin-like growth factors (IGFs) are important mitogens that are present in many body fluids, where they are commonly bound with high affinity to IGF binding proteins (IGFBPs). We investigated human urine for the pres-ence of IGFBPs. Western ligand blots of concentrated, dialyzed normal urine disclosed the presence of two major bands with IGF binding activity, one at 40-44 kilodaltons and another at 31 kDa. Deglycosylation with endoglycosidase F, and immunoprecipitation with αHEC1 antibody revealed these proteins to be hIGFBP-3 and hIGFBP-2, respectively. Comparison of IGFBPs in normal serum and urine showed a reversal of the hIGFBP-2/hIGFBP-3 ratio in urine compared to serum, with hIGFBP-2 being the predominant binding protein in normal urine. The 150 kDa form of hIGFBP-3 was absent in normal urine. In patients with renal disease, the urinary IGFBP (U-IGFBP) pattern was altered. Patients with glomerular disease and proteinuria had elevated U-hIGFBP-3, whereas patients with renal failure who displayed increased urinary β-2-microglobulin had a dramatic increase in U-hIGFBP-1, in the face of normal serum IGFBP profiles. In conclusion, we have documented the presence of IGFBPs in the urine of normal and diseased individuals. The presence of IGFBPs in urine may complicate the assessment of IGF measurements in urine. U-IGFBPs may be potential clinical markers in renal diseases. Additional studies are required before the origin of urinary IGFBPs in both normal and pathological conditions will be definitively established.",
author = "Yukihiro Hasegawa and Pinchas Cohen and Peter Yorgin and Rosenfeld, {Ronald (Ron)}",
year = "1992",
month = "4",
language = "English (US)",
volume = "74",
pages = "830--835",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Characterization of urinary insulin-like growth factor binding proteins

AU - Hasegawa, Yukihiro

AU - Cohen, Pinchas

AU - Yorgin, Peter

AU - Rosenfeld, Ronald (Ron)

PY - 1992/4

Y1 - 1992/4

N2 - The insulin-like growth factors (IGFs) are important mitogens that are present in many body fluids, where they are commonly bound with high affinity to IGF binding proteins (IGFBPs). We investigated human urine for the pres-ence of IGFBPs. Western ligand blots of concentrated, dialyzed normal urine disclosed the presence of two major bands with IGF binding activity, one at 40-44 kilodaltons and another at 31 kDa. Deglycosylation with endoglycosidase F, and immunoprecipitation with αHEC1 antibody revealed these proteins to be hIGFBP-3 and hIGFBP-2, respectively. Comparison of IGFBPs in normal serum and urine showed a reversal of the hIGFBP-2/hIGFBP-3 ratio in urine compared to serum, with hIGFBP-2 being the predominant binding protein in normal urine. The 150 kDa form of hIGFBP-3 was absent in normal urine. In patients with renal disease, the urinary IGFBP (U-IGFBP) pattern was altered. Patients with glomerular disease and proteinuria had elevated U-hIGFBP-3, whereas patients with renal failure who displayed increased urinary β-2-microglobulin had a dramatic increase in U-hIGFBP-1, in the face of normal serum IGFBP profiles. In conclusion, we have documented the presence of IGFBPs in the urine of normal and diseased individuals. The presence of IGFBPs in urine may complicate the assessment of IGF measurements in urine. U-IGFBPs may be potential clinical markers in renal diseases. Additional studies are required before the origin of urinary IGFBPs in both normal and pathological conditions will be definitively established.

AB - The insulin-like growth factors (IGFs) are important mitogens that are present in many body fluids, where they are commonly bound with high affinity to IGF binding proteins (IGFBPs). We investigated human urine for the pres-ence of IGFBPs. Western ligand blots of concentrated, dialyzed normal urine disclosed the presence of two major bands with IGF binding activity, one at 40-44 kilodaltons and another at 31 kDa. Deglycosylation with endoglycosidase F, and immunoprecipitation with αHEC1 antibody revealed these proteins to be hIGFBP-3 and hIGFBP-2, respectively. Comparison of IGFBPs in normal serum and urine showed a reversal of the hIGFBP-2/hIGFBP-3 ratio in urine compared to serum, with hIGFBP-2 being the predominant binding protein in normal urine. The 150 kDa form of hIGFBP-3 was absent in normal urine. In patients with renal disease, the urinary IGFBP (U-IGFBP) pattern was altered. Patients with glomerular disease and proteinuria had elevated U-hIGFBP-3, whereas patients with renal failure who displayed increased urinary β-2-microglobulin had a dramatic increase in U-hIGFBP-1, in the face of normal serum IGFBP profiles. In conclusion, we have documented the presence of IGFBPs in the urine of normal and diseased individuals. The presence of IGFBPs in urine may complicate the assessment of IGF measurements in urine. U-IGFBPs may be potential clinical markers in renal diseases. Additional studies are required before the origin of urinary IGFBPs in both normal and pathological conditions will be definitively established.

UR - http://www.scopus.com/inward/record.url?scp=0026562997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026562997&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 830

EP - 835

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -